EquitySector - HealthcareVery High Risk
NAV (03-Dec-24)
Returns (Since Inception)
Fund Size
₹29 Cr
Expense Ratio
0.22%
ISIN
INF247L01BB1
Minimum SIP
-
Exit Load
-
Inception Date
29 Jul 2022
Equity | ₹28.59 Cr | 99.83% |
Others | ₹0.05 Cr | 0.17% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹4.41 Cr | 15.41% |
Cipla Ltd | Equity | ₹1.91 Cr | 6.68% |
Dr Reddy's Laboratories Ltd | Equity | ₹1.72 Cr | 5.99% |
Divi's Laboratories Ltd | Equity | ₹1.66 Cr | 5.80% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹1.66 Cr | 5.80% |
Apollo Hospitals Enterprise Ltd | Equity | ₹1.56 Cr | 5.45% |
Lupin Ltd | Equity | ₹1.17 Cr | 4.08% |
Aurobindo Pharma Ltd | Equity | ₹0.87 Cr | 3.03% |
Fortis Healthcare Ltd | Equity | ₹0.72 Cr | 2.52% |
Alkem Laboratories Ltd | Equity | ₹0.67 Cr | 2.35% |
Torrent Pharmaceuticals Ltd | Equity | ₹0.65 Cr | 2.26% |
Mankind Pharma Ltd | Equity | ₹0.59 Cr | 2.06% |
Glenmark Pharmaceuticals Ltd | Equity | ₹0.56 Cr | 1.95% |
Zydus Lifesciences Ltd | Equity | ₹0.56 Cr | 1.94% |
Ipca Laboratories Ltd | Equity | ₹0.47 Cr | 1.65% |
Laurus Labs Ltd | Equity | ₹0.43 Cr | 1.49% |
Suven Pharmaceuticals Ltd | Equity | ₹0.37 Cr | 1.29% |
Piramal Pharma Ltd | Equity | ₹0.36 Cr | 1.26% |
Syngene International Ltd | Equity | ₹0.34 Cr | 1.20% |
Abbott India Ltd | Equity | ₹0.34 Cr | 1.18% |
Biocon Ltd | Equity | ₹0.31 Cr | 1.08% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹0.31 Cr | 1.08% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹0.29 Cr | 1.03% |
Gland Pharma Ltd | Equity | ₹0.29 Cr | 1.01% |
Ajanta Pharma Ltd | Equity | ₹0.29 Cr | 1.01% |
Natco Pharma Ltd | Equity | ₹0.28 Cr | 0.97% |
Neuland Laboratories Limited | Equity | ₹0.28 Cr | 0.97% |
Dr. Lal PathLabs Ltd | Equity | ₹0.25 Cr | 0.88% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.24 Cr | 0.85% |
Concord Biotech Ltd | Equity | ₹0.24 Cr | 0.83% |
Strides Pharma Science Ltd | Equity | ₹0.23 Cr | 0.82% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.22 Cr | 0.77% |
Poly Medicure Ltd | Equity | ₹0.22 Cr | 0.76% |
Global Health Ltd | Equity | ₹0.2 Cr | 0.71% |
Jubilant Pharmova Ltd | Equity | ₹0.2 Cr | 0.70% |
Wockhardt Ltd | Equity | ₹0.2 Cr | 0.69% |
Narayana Hrudayalaya Ltd | Equity | ₹0.19 Cr | 0.66% |
Granules India Ltd | Equity | ₹0.18 Cr | 0.64% |
Rainbow Childrens Medicare Ltd | Equity | ₹0.18 Cr | 0.63% |
Pfizer Ltd | Equity | ₹0.17 Cr | 0.60% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹0.14 Cr | 0.49% |
Alembic Pharmaceuticals Ltd | Equity | ₹0.14 Cr | 0.48% |
Sanofi India Ltd | Equity | ₹0.13 Cr | 0.47% |
Marksans Pharma Ltd | Equity | ₹0.13 Cr | 0.46% |
Metropolis Healthcare Ltd | Equity | ₹0.12 Cr | 0.42% |
Jupiter Life Line Hospitals Ltd | Equity | ₹0.11 Cr | 0.39% |
AstraZeneca Pharma India Ltd | Equity | ₹0.11 Cr | 0.37% |
Vijaya Diagnostic Centre Ltd | Equity | ₹0.1 Cr | 0.36% |
Ami Organics Ltd | Equity | ₹0.1 Cr | 0.36% |
Shilpa Medicare Ltd | Equity | ₹0.1 Cr | 0.35% |
Procter & Gamble Health Ltd | Equity | ₹0.09 Cr | 0.32% |
Caplin Point Laboratories Ltd | Equity | ₹0.09 Cr | 0.32% |
Glenmark Life Sciences Ltd | Equity | ₹0.07 Cr | 0.25% |
Aarti Pharmalabs Ltd | Equity | ₹0.07 Cr | 0.24% |
Morepen Laboratories Ltd | Equity | ₹0.06 Cr | 0.21% |
FDC Ltd | Equity | ₹0.06 Cr | 0.21% |
Kovai Medical Center & Hospital Ltd | Equity | ₹0.06 Cr | 0.20% |
Indegene Ltd | Equity | ₹0.06 Cr | 0.20% |
Advanced Enzyme Technologies Ltd | Equity | ₹0.05 Cr | 0.18% |
Net Receivables / (Payables) | Cash | ₹0.05 Cr | 0.17% |
Orchid Pharma Ltd | Equity | ₹0.05 Cr | 0.17% |
Sun Pharma Advanced Research Co Ltd | Equity | ₹0.05 Cr | 0.17% |
Sequent Scientific Ltd | Equity | ₹0.05 Cr | 0.16% |
Solara Active Pharma Sciences Ltd Ordinary Shares | Equity | ₹0.05 Cr | 0.16% |
Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹0.04 Cr | 0.14% |
HealthCare Global Enterprises Ltd | Equity | ₹0.04 Cr | 0.14% |
Indraprastha Medical Corp Ltd | Equity | ₹0.04 Cr | 0.14% |
Krsnaa Diagnostics Ltd | Equity | ₹0.04 Cr | 0.13% |
Unichem Laboratories Ltd | Equity | ₹0.04 Cr | 0.13% |
Aarti Drugs Ltd | Equity | ₹0.04 Cr | 0.13% |
Supriya Lifescience Ltd | Equity | ₹0.04 Cr | 0.12% |
Hikal Ltd | Equity | ₹0.03 Cr | 0.11% |
Thyrocare Technologies Ltd | Equity | ₹0.03 Cr | 0.11% |
Dishman Carbogen Amics Ltd | Equity | ₹0.03 Cr | 0.10% |
Innova Captab Ltd | Equity | ₹0.03 Cr | 0.09% |
Gufic Biosciences Ltd | Equity | ₹0.03 Cr | 0.09% |
Blue Jet Healthcare Ltd | Equity | ₹0.03 Cr | 0.09% |
Indoco Remedies Ltd | Equity | ₹0.03 Cr | 0.09% |
RPG Life Sciences Ltd | Equity | ₹0.02 Cr | 0.08% |
Syncom Formulation (India) Ltd | Equity | ₹0.02 Cr | 0.07% |
IOL Chemicals And Pharmaceuticals Ltd | Equity | ₹0.02 Cr | 0.07% |
Hester Biosciences Ltd | Equity | ₹0.02 Cr | 0.07% |
Gujarat Themis Biosyn Ltd | Equity | ₹0.02 Cr | 0.07% |
SMS Pharmaceuticals Ltd | Equity | ₹0.02 Cr | 0.07% |
Windlas Biotech Ltd | Equity | ₹0.02 Cr | 0.07% |
Bliss GVS Pharma Ltd | Equity | ₹0.02 Cr | 0.06% |
Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹0.02 Cr | 0.06% |
Suven Life Sciences Ltd | Equity | ₹0.02 Cr | 0.06% |
Sigachi Industries Ltd | Equity | ₹0.02 Cr | 0.06% |
Kopran Ltd | Equity | ₹0.02 Cr | 0.06% |
Themis Medicare Ltd | Equity | ₹0.02 Cr | 0.06% |
Novartis India Ltd | Equity | ₹0.02 Cr | 0.05% |
Shalby Ltd | Equity | ₹0.01 Cr | 0.05% |
Lincoln Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.05% |
Tarsons Products Ltd | Equity | ₹0.01 Cr | 0.05% |
GPT Healthcare Ltd | Equity | ₹0.01 Cr | 0.04% |
Vimta Labs Ltd | Equity | ₹0.01 Cr | 0.03% |
NGL Fine-Chem Ltd | Equity | ₹0.01 Cr | 0.03% |
KMC Speciality Hospitals (India) Ltd | Equity | ₹0.01 Cr | 0.02% |
Sastasundar Ventures Ltd | Equity | ₹0.01 Cr | 0.02% |
Large Cap Stocks
45.59%
Mid Cap Stocks
28.41%
Small Cap Stocks
24.86%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹28.16 Cr | 98.32% |
Basic Materials | ₹0.15 Cr | 0.54% |
Standard Deviation
This fund
--
Cat. avg.
15.68%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.87
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.61
Higher the better
ISIN INF247L01BB1 | Expense Ratio 0.22% | Exit Load - | Fund Size ₹29 Cr | Age 2 years 4 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹28.64 Cr | - |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹881.52 Cr | - |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹881.52 Cr | - |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹40.84 Cr | - |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹208.21 Cr | - |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹208.21 Cr | - |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2770.21 Cr | - |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2770.21 Cr | - |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹852.28 Cr | - |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹19.81 Cr | - |
Total AUM
₹78,892 Cr
Address
Motilal Oswal Tower, Mumbai, 400 025
Your principal amount will be at Very High Risk